Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | RGD Reference | Notes | Source | Original Reference(s) | ZNF442 | Human | (+)-catechin | multiple interactions | EXP | | 6480464 | [Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of ZNF442 mRNA | CTD | PMID:24763279 | ZNF442 | Human | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF442 mRNA | CTD | PMID:22079256 | ZNF442 | Human | 3-phenylprop-2-enal | increases expression | EXP | | 6480464 | cinnamaldehyde results in increased expression of ZNF442 mRNA | CTD | PMID:19524605 | ZNF442 | Human | 4-hydroxyphenyl retinamide | decreases expression | ISO | Gm2026 (Mus musculus) | 6480464 | Fenretinide results in decreased expression of ZNF442 mRNA | CTD | PMID:28973697 | ZNF442 | Human | acrylamide | increases expression | EXP | | 6480464 | Acrylamide results in increased expression of ZNF442 mRNA | CTD | PMID:32763439 | ZNF442 | Human | aflatoxin B1 | affects expression | EXP | | 6480464 | Aflatoxin B1 affects the expression of ZNF442 protein | CTD | PMID:20106945 | ZNF442 | Human | aristolochic acid A | increases expression | EXP | | 6480464 | aristolochic acid I results in increased expression of ZNF442 mRNA | CTD | PMID:33212167 | ZNF442 | Human | benzo[a]pyrene | decreases methylation | EXP | | 6480464 | Benzo(a)pyrene results in decreased methylation of ZNF442 5' UTR; Benzo(a)pyrene results in decreased methylation of more ... | CTD | PMID:27901495 | ZNF442 | Human | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of ZNF442 mRNA | CTD | PMID:20106945 | ZNF442 | Human | doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of ZNF442 mRNA | CTD | PMID:29803840 | ZNF442 | Human | leflunomide | increases expression | EXP | | 6480464 | leflunomide results in increased expression of ZNF442 mRNA | CTD | PMID:28988120 | ZNF442 | Human | okadaic acid | increases expression | EXP | | 6480464 | Okadaic Acid results in increased expression of ZNF442 mRNA | CTD | PMID:38832940 | ZNF442 | Human | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF442 mRNA | CTD | PMID:22079256 | ZNF442 | Human | potassium chromate | increases expression | EXP | | 6480464 | potassium chromate(VI) results in increased expression of ZNF442 mRNA | CTD | PMID:22079256 | ZNF442 | Human | resorcinol | decreases expression | EXP | | 6480464 | resorcinol results in decreased expression of ZNF442 mRNA | CTD | PMID:22623647 | ZNF442 | Human | resveratrol | multiple interactions | EXP | | 6480464 | [Plant Extracts co-treated with Resveratrol] results in increased expression of ZNF442 mRNA | CTD | PMID:23557933 | ZNF442 | Human | sunitinib | decreases expression | EXP | | 6480464 | Sunitinib results in decreased expression of ZNF442 mRNA | CTD | PMID:31533062 | ZNF442 | Human | urethane | increases expression | EXP | | 6480464 | Urethane results in increased expression of ZNF442 mRNA | CTD | PMID:28818685 | ZNF442 | Human | valproic acid | increases methylation | EXP | | 6480464 | Valproic Acid results in increased methylation of ZNF442 gene | CTD | PMID:29154799 | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||






















